Santaris Pharma A/S gained commercial validation for its Locked Nucleic Acid (LNA) oligonucleotide analogue chemistry through a co-development and commercialization oncology deal with Enzon Pharmaceuticals. The agreement is worth in excess of $200 million in up-front and milestone payments. (BioWorld International) Read More
